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Abstract. Ovarian cancer is the second most common 
gynaecological malignancy and was diagnosed in over 7,000 
women in 2011 in the UK. There are currently no reliable 
biomarkers available for use in a regular screening assay for 
ovarian cancer and due to characteristic late presentation (78% 
in stages III and IV) ovarian cancer has a low survival rate 
(35% after 10 years). The mTOR pathway is a central regulator 
of growth, proliferation, apoptosis and angiogenesis; providing 
balance between available resources such as amino acids 
and growth factors, and stresses such as hypoxia, to control 
cellular behaviour accordingly. Emerging data links mTOR 
with the aetiopathogenesis of ovarian cancer. We hypothesised 
that mTOR inhibitors could play a therapeutic role in ovarian 
cancer treatment. In this study we began by validating the 
expression of four main mTOR pathway components, mTOR, 
DEPTOR, rictor and raptor, at gene and protein level in in vitro 
models of endometrioid (MDAH-2774) and clear cell (SKOV3) 
ovarian cancer using qPCR and ImageStream technology. 
Using a wound healing assay we show that inhibition of the 
mTOR pathway using rapamycin, rapalogues, resveratrol and 
NVP BEZ-235 induces a cytostatic and not cytotoxic response 
up to 18 h in these cell lines. We extended these findings up 
to 72 h with a proliferation assay and show that the effects of 
inhibition of the mTOR pathway are primarily mediated by 
the dephosphorylation of p70S6 kinase. We show that mTOR 
inhibition does not involve alteration of mTOR pathway 
components or induce caspase 9 cleavage. Preclinical studies 
including ovarian tissue of ovarian cancer patients, unaffected 
controls and patients with unrelated gynaecological conditions 
show that DEPTOR is reliably upregulated in ovarian cancer.
Introduction
Ovarian carcinoma is the gynaecologic malignancy associated 
with the highest mortality in industrialised countries, with a 
reported 5-year survival rate of <30% (1). The prognosis for 
patients with ovarian cancer is determined by conventional 
factors such as surgical stage and histological grade and type. 
Nevertheless, no single molecular profile has helped identify 
the most aggressive tumours or aided in the guidance of 
suitable therapeutic strategies for specific patients. Due to 
the indefinite presentation of ovarian cancer, it is often not 
diagnosed until it has reached stage 3 or 4, at which point the 
5-year survival rate drops significantly; the mortality rate has 
remained unchanged for >30 years. Despite this, due to the 
lack of a known, reliable biomarker for the disease, there is 
currently no ovarian cancer screening programme used by the 
National Health Service. Many carcinomas activate growth 
factor receptor signalling pathways that exhibit genetic altera-
tions involving either the receptor, or other factors that drive 
the proliferation. Interestingly, several pathways converge on 
the highly conserved serine/threonine kinase mTOR (2).
The mTOR pathway is an integral hub of growth and 
proliferation; gauging external energy, growth factor and 
stress signals. It influences processes such as protein synthesis, 
lipid biogenesis and autophagy to find the balance between 
anabolic and catabolic mechanisms in relation to the whole-
organism state. The PI3K/Akt/mTOR pathway is activated in 
advanced stage disease and inhibition of this pathway with 
inhibitors to Akt or its downstream effector, mTOR, increases 
chemo-sensitivity to paclitaxel in ovarian carcinoma cell lines 
(3). Cell signalling by mTOR plays a critical role in protein 
synthesis and proliferation of both normal and malignant cells. 
mTOR and one of its substrates, S6 kinase, is activated in 
ovarian cancer cells and inhibition of the mTOR pathways has 
anti-proliferative effects (4). Rapamycin inhibits the growth 
of a broad spectrum of malignancies including pancreatic 
cancer, leukaemia and B-cell lymphoma (5). Rapamycin (an 
mTOR inhibitor) may act as a substrate for the MDR trans-
porter P-glycoprotein and consequently limit its utility in 
some tumours (6). In a transgenic mouse model of ovarian 
cancer, treatment with the rapamycin analogue everolimus (an 
inhibitor of mTOR) exhibited a delay in cancer progression (7). 
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Deforolimus, another rapamycin analogue has been shown to 
inhibit sarcoma and endometrial cancer growth both in vitro 
and in vivo (8). In addition, the rapalogue temsirolimus has 
exhibited therapeutic benefit when administered to patients 
with clear cell carcinoma of the ovary (9).
Moreover, a limitation to successful cancer chemotherapy 
treatment is the acquisition of drug resistance. In advanced-
stage ovarian cancer, mTOR pathway is upregulated, and 
inhibition of this pathway increases chemosensitivity in 
ovarian carcinoma cell lines. Previous data from our labora-
tory has revealed significant upregulation of DEPTOR in 
paclitaxel-resistant (TaxR) SKOV-3TaxR and PEO1TaxR cell 
lines. SKOV-3TaxR exhibited downregulation of RICTOR, 
RAPTOR and mTOR, whereas PEO1-TaxR showed down-
regulation of RAPTOR and upregulation of RICTOR and 
mTOR (10).
In this study, we investigated the effects of rapalogues on 
ovarian cancer using two cell lines (SKOV3 and MDAH-2774) 
as in vitro experimental models. We expanded on these obser-
vations by mapping the expression of mTOR components 
(including DEPTOR, rictor, raptor and S6K) in tissue and 
peripheral blood of ovarian cancer patients.
Materials and methods
Ovarian cancer clinical samples. Gene expression of mTOR, 
Deptor, Rictor and Raptor were mapped in 12 clinical samples 
from ovarian cancer patients using qPCR. Clinical samples 
were of ovarian origin and obtained from patients at the 1st 
Department of Obstetrics and Gynecology, ‘Papageorgiou’ 
General Hospital, Medical School, Aristotle University, 
Thessaloniki, Greece. Ethical permission was obtained locally. 
The majority of ovarian cancers were deemed to be third grade 
(10 out of 12) and at stage 3 (11 out of 12).
RNA isolation, cDNA synthesis and quantitative RT-PCR. 
Ovarian tissue (40 mg) was lysed in a Qiagen Tissue Lyser II 
(Qiagen, Hilden, Germany) for 2 min with a 3-mm stainless 
steel ball bearing. RNA was extracted from tissue lysate using 
the GenElute™ mRNA MiniPrep kit (Sigma-Aldrich, MO, 
USA), a silica membrane/spin column method, and stored at 
-80˚C until further use.
cDNA was synthesised from mRNA using Superscript II 
(Invitrogen, MA, USA). cDNA concentration was normalised 
using RNA concentrations determined by NanoDrop (Thermo 
Scientific, MA, USA) and was synthesised to a concentration 
of either 500 or 1,000 ng.
Primers. Relative expression of mTOR, DEPTOR, rictor and 
raptor (Table I) were assessed by quantitative PCR (Q-PCR) 
on an xxpress® (BJS Biotechnologies, Middlesex, UK) 
thermal cycler using Kapa SYBR Fast Universal Mastermix 
(Kapa Biosystems, MA, USA). According to MIQE (minimum 
information for publication of quantitative real-time PCR 
experiments) guidelines (11), an assessment of the most stably 
expressed reference genes specific to the samples used must 
be carried out prior to any qPCR experiment. In light of this, 
a selection of 8 ovarian clinical samples were assessed using 
the geNorm human 12 gene kit (Primer Design, Southampton, 
UK) according to the manufacturer's instructions. Reference 
gene expression stability was analysed using qbaseplus soft-
ware (Biogazelle, Zwijnaarde, Belgium). Primers for mTOR, 
Deptor, Rictor and Raptor were used as previously described 
(10). qPCR data were analysed using the ΔCq method whereby 
the Cq of the endogenous control was subtracted from the Cq 
of the gene of interest and an RQ (relative quantity) value was 
calculated by finding 2-ΔCq (11,12). Where more than one refer-
ence gene was used, the RQ values were averaged. A Student's 
t-test was used to calculate statistical significance.
Cell lines and treatments. SKOV3 (human ovarian clear cell 
adenocarcinoma) and MDAH-2774 (human ovarian endo-
metrioid adenocarcinoma) cell lines were purchased from 
American Type Culture Collection (ATCC, Rockville, MD, 
USA) and were used as models for epithelial ovarian cancer. 
Both cell lines were cultured at 37˚C/5% CO2 in DMEM 
supplemented with 10% FBS, 1% penicillin/streptomycin 
and 1% L-glutamine (all Gibco, MA, USA). SKOV3 and 
MDAH-2774 cells were treated with specific mTOR inhibitors 
(Table II) at two concentrations for three lengths of time, 24, 
48 and 72 h.
Western blotting. Proteins extracted from cultured cells 
following treatments were assessed for cleaved and total 
caspase 9 and 3 levels, hallmarks of apoptosis, and phospho-
p70S6K. Proteins were separated by mass by SDS-PAGE 
in a 12.5% resolving gel. The separated proteins were then 
electrophoretically transferred onto a nitrocellulose membrane 
(Thermo Scientific) in wet-transfer buffer. The membrane 
was probed using primary antibody for caspases 3 and 9 and 
phospho (Thr389) p70S6K (Cell Signaling Technology, MA, 
USA) and an anti-rabbit HRP-conjugated secondary antibody 
diluted in 5% bovine serum albumin/TBS Tween. The devel-
oped western blots were analysed densitometrically using 
ImageJ software (National Institutes of Health, MD, USA) and 
cleaved caspase 9 was normalised internally against uncleaved 
caspase 9. The data were analysed statistically using Student's 
t-test.
Ovarian tissue microarray. Unstained paraffin-embedded 
tissue micro-array slides containing 70 ovarian cancers 
were obtained from US Biomax (MD, USA). The paraffin-
embedded slides were deparaffinised and rehydrated by a 
series of washes in reducing concentrations of ethanol (100, 
95, 70 and 50%) followed by rinsing in tap water for 10 min. 
Antigen retrieval was accomplished by boiling slides in 
sodium citrate (pH 6.0) for 20 min in a microwave. Slides 
were washed in 0.4% of PBS Tween for 5 min and then 
incubated for 15 min in PBS containing 0.3% H2O2 to elimi-
nate endogenous peroxidase activity. Blocking was carried 
out with 5% goat serum, followed by 48-h incubation with 
primary antibody (p70S6K). After several washes with PBS, 
slides were incubated with HRP conjugated secondary anti-
body for 60 min. Further washing in PBS Tween was carried 
out for 20 min before performing staining. Slides were then 
subjected to DAB staining, counterstained with haematoxylin 
and washed with 0.1% sodium bicarbonate. Slides were 
analysed for immunoreactivity of p70S6K by a light micro-
scope and positive results were measured by the percentage 
of positive tumour cells.
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Proliferation assay. Proliferation, death and viability of 
the cells were assessed after treatment using a Countess 
Automated Cell Counter (Invitrogen) and trypan blue stain. 
Media was aspirated from the cells which were then incubated 
with 200 µl of trypLE™ Express (Thermo Scientific) per well 
and manually agitated to detach the cells. The cells were resus-
pended in 800 µl of appropriate media to make 1 ml of cell 
suspension in total. An equal volume of cell suspension was 
mixed thoroughly with trypan blue stain (0.4%, trypan blue is 
selectively absorbed by dead cells) and applied to a Countess™ 
cell counting chamber slide (Invitrogen). Three readings were 
taken per sample and an average value calculated.
Wound healing assay. Cells were assessed for their ability 
to close an artificially created gap in cell growth area. One 
confluent T-75 cell culture flask was seeded per three 6-well 
plates with 2 ml appropriate media per well and grown until 
there was a confluent monolayer. A 20-µl pipette tip was used 
to create a ‘scratch’ in growth area perpendicular to a line 
drawn on the underside of the well in marker pen. The media 
was then aspirated and replaced with treated media. Cells were 
placed under a Zeiss Axiovert 200M microscope and images 
were recorded at 0, 6, 12 and 18 h. The perpendicular line of 
marker was used as a landmark to ensure that an image of the 
same area was taken at each time-point.
ImageStream. Protein expression and localisation of mTOR, 
DEPTOR, rictor and raptor was investigated using ImageStream 
Table I. The primer sequences for the mTOR, Deptor, Rictor 
and Raptor genes used in qPCR experiments for the clinical 
samples and the in vitro experiments.
Name Product Strand Size Sequence
 length   (bases)
 (bases)
mTOR 135 Forward 20 tgccaactaccttcggaacc
  Reverse 20 gctcgcttcacctcaaattc
Deptor 202 Forward 20 caccatgtgtgtgatgagca
  Reverse 20 tgaaggtgcgctcatacttg
Rictor 117 Forward 20 ggaagcctgttgatggtgat
  Reverse 20 ggcagcctgttttatggtgt
Raptor 170 Forward 20 actgatggagtccgaaatgc
  Reverse 20 tcatccgatccttcatcctc
Table II. Details of the mTOR pathway inhibitory agents used 
in this study.
Inhibitor Mode of action Concentrations
Rap Allosteric mTOR inhibitor   20 nM   100 nM
Eve    20 nM   100 nM
Def  100 nM 1,000 nM
Tem    10 nM   100 nM
Res Dual mTOR (via DEPTOR)    25 µM     50 µM
 and PI3 kinase (via ATP
 binding site) inhibitor
BEZ Dual mTOR and PI3 kinase   10 nM 100 nM
 inhibitor via ATP binding
 sites of both
Figure 1. Gene expression analysis of mTOR pathway components, mTOR, 
DEPTOR, rictor and raptor, in SKOV3 and MDAH-2774 cells. SKOV3 and 
MDAH-2774 cells were seeded in 6-well plates at 100,000 cells per well 
and cultured under basal conditions over a 72-h period. qPCR was per-
formed in cDNA synthesised from extracted mRNA after 24 (A), 48 (B) and 
72 h (C) using primers for mTOR, DEPTOR, rictor and raptor corrected with 
YWHAZ (reference gene). Error bars depict standard deviation.
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high resolution flow cytometry (Merck Millipore, Darmstadt, 
Germany). Media was aspirated from the cells which were 
then incubated with TrypLE™ Express (Invitrogen). Washes 
in PBS were performed to remove debris. The cells were resus-
pended and incubated in 4% paraformaldehyde (PFA, Sigma, 
MO, USA) for 7 min and the PFA removed. Further washed in 
PBS were performed and stored ice-cold at -20˚C until further 
use. The cells were incubated in blocking buffer (5% bovine 
serum in PBS) for 30 min followed by the appropriate primary 
antibody (diluted in blocking buffer) overnight at 4˚C. Washes 
were performed with PBS and incubated in secondary anti-
body (diluted in blocking buffer) for 30 min. After secondary 
antibody incubation the cells were washed again in PBS to 
remove any remaining antibody. PBS was removed and the 
cells were resuspended in 100 µl Accumax (Innovative Cell 
Technologies, CA, USA) to dissociate any cellular aggregates. 
Draq5 nuclear stain (1 µl) was added before visualisation on 
ImageStream.
Statistical analysis. Changes observed in experiments were 
assessed for statistical significance using the Student's t-test. 
An assessment for homoscedasticity (variance) of data from 
each category was made using the F-test. If homoscedasticity 
was proven, an unpaired, two-tailed Student's t-test was 
performed to assess significance in all cases as no matched 
pairs of samples were used. If data were not homoscedastic, an 
unpaired, two-tailed Student's t-test with Welch's correction 
was performed to account for variance. All statistical tests 
were performed using GraphPad Prism® software (GraphPad 
Software Inc., CA, USA). P-values were denoted on graphs if 
significant (p<0.05).
Results
Expression of mTOR components in ovarian cancer cell 
lines. Prior to studying the effects of mTOR inhibitors, we 
assessed the basal expression of mTORC1 and mTORC2 
components in both cell lines over 72 h. All key components, 
i.e., mTOR, DEPTOR, rictor and raptor are expressed in both 
cell lines in a similar fashion over the course of 72 h (Fig. 1). 
The predominant component was raptor, with DEPTOR 
demonstrating minimal expression in both cell lines under 
basal conditions. Following qPCR analysis, we used the 
state-of-the-art ImageStream technology that combines flow 
cytometry with cell imaging for parallel quantification and 
visualisation of single cells. Strong cytoplasmic and nuclear 
expression for both mTOR (Fig. 2A) and DEPTOR (Fig. 2B) 
was evident in most of ovarian cancer (MDAH-2774) single 
cells studied. The expression of rictor (Fig. 2C) and raptor 
(Fig. 2D) was primarily nuclear/cytoplasmic. Similar cellular 
distribution of these key components of both mTORC1 and 
mTORC2 complexes was evident in SKOV3 cells (data not 
shown).
mTOR inhibitors compromise migratory capacity and cell 
proliferation of ovarian cancer cells in vitro. Wound healing 
assays can give a visual indication of cell proliferative and 
migratory capacity spatially in vitro. Rapamycin (20 and 
100 nM) was selected from the rapalogues (since they have 
a similar chemical structure) and resveratrol (25 and 50 µM) 
and BEZ (10 and 100 nM) were used as they are mechanisti-
cally different to the rapalogues and one another. SKOV3 cells 
showed a marked growth into the wound which was not shared 
by any of the inhibitor-treated cells (Fig. 3). In MDAH-2774 
cells, a more modest response was recorded using the same 
inhibitors (data not shown).
Based on the wound healing data, we have decided to 
expand on the repertoire of rapalogues; therefore, trypan 
blue staining was used to make an assessment of the prolif-
erative capacity of SKOV3 and MDAH-2774 cells up to 72 h 
following treatment with the following inhibitors: rapamycin 
(Rap, 20 and 100 nM), everolimus (Eve, 20 and 100 nM), defo-
rolimus (Def, 100 and 1,000 nM), temsirolimus (Tem, 10 and 
100 nM), resveratrol (Res, 25 and 50 µM), and NVP BEZ-235 
(BEZ, 10 and 100 nM). Treatment of the SKOV3 cell line 
with Rap and the rapalogues showed a non-dose-dependent 
decrease in viable cells (Fig. 4, Rap 100 nM: p=0.0355 at 72 h, 
Eve 100 nM: p=0.0047 at 72 h, Tem 100 nM: p=0.0446 at 72 h, 
Def 1,000 nM did not reach statistical significance: p=0.0597). 
The decrease in viable cells shown by Res and BEZ was dose-
dependent (Fig. 4, Res 50 µM: p<0.0001 at 72 h, BEZ 100 nM: 
p<0.0001 at 72 h).
Viable cell count in MDAH-2774 cells was differentially 
affected by Rap (Rap 100 nM: p=0.0013 at 48 h), rapalogues 
(Def 1,000 nM: p=0.0004 at 48 h, Tem 100 nM: p=0.0065 at 
72 h) or Res (Res 50 µM: p=0.0014 at 72 h) treatment (Fig. 5). 
BEZ treatment at 10 nM concentration did not have an effect 
on viable cell count, but at 100 nM, proliferation was almost 
entirely eliminated (Fig. 5, p<0.0001 at 48 and 72 h).
Effects of mTOR inhibitors on caspase 9 and phospho-
p70S6K. Cleavage of caspase 9 could be seen after all 
treatments and time-points in both cell lines. When analysed 
densitometrically, SKOV3 cells showed a clear trend of highest 
caspase 9 cleavage at 24 h and lessening over time in each case 
(Fig. 6A). These changes did not reach statistical significance 
in comparison to controls; however, significant changes were 
found between time-points in Rap 20 nM (p=0.0069, 24-72 h), 
Rap 100 nM (p=0.00159, 24-72 h), Def 1,000 nM (p=0.0496, 
24-48 h), Res 25 µM (p=0.0367, 24-48 h and p=0.0353, 
24-72 h) and Res 50 µM (p=0.0483, 24-72 h) treatments, indi-
cating that cleavage of caspase 9 does decrease significantly 
over time in these cases. However, MDAH-2774 cells showed 
no increase in caspase 9 cleavage upon treatment with mTOR 
inhibitors (Fig. 6B and C).
Phosphorylation status of p70S6K was examined to better 
understand the activity of the mTOR pathway after inhibition. 
At 24, 48 and 72 h, the basal phosphorylation of p70S6K was 
completely abolished in both MDAH-2774 and SKOV3 (Fig. 7) 
cells treated with rapamycin, all of the other rapalogues and at 
100 nM of BEZ treatment. In SKOV3 cells treated with Res, 
de-phosphorylation of p70S6K only occurred at 50 µM of Res 
at 24 and 48 h. Res treatment did not dephosphorylate p70S6K 
at 25 or 50 µM in MDAH-2774 cells.
Expression of S6K in ovarian tissue array. Based on the 
previous data on p70S6K, it is evident that the mTORC1 
activity is compromised upon treatment with mTOR inhibi-
tors. Given the significance that p70S6K has in moderating the 
activity of mTORC1, we studied the cellular distribution of this 
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Figure 2. ImageStream high resolution flow cytometry analysis of mTOR (A), DEPTOR (B), rictor (C) and raptor (D) protein expression in MDAH-2774 cells 
grown under basal conditions. MDAH-2774 cells were fixed in paraformaldehyde and stained with antibodies for mTOR, DEPTOR, rictor and raptor and an 
Alexa Fluor® conjugated secondary antibody before visualisation. mTOR, DEPTOR, rictor and raptor were expressed at protein level in this cell line.
Figure 3. Wound healing analysis of SKOV3 cells treated with rapamycin (Rap), resveratrol (Res) and NVP BEZ-235 (BEZ). SKOV3 cells were seeded in 
6-well plates and grown to a confluent monolayer. A scratch was created in the growth area with a p200 pipette tip and the cells were cultured in media 
containing either Rap (20 or 100 nM), Res (25 or 50 µM) or BEZ (10 or 100 nM). The ‘wound’ was monitored over an 18-h period and images recorded at 0, 
6, 12 and 18 h. mTOR pathway inhibition induced retardation of growth into the created gap.
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Figure 5. Proliferation and survival analysis of MDAH-2774 cells following treatment with Rap [(A) 20 and 100 nM], everolimus [(B) Eve, 20 and 100 nM], 
deforolimus [(C) Def, 100 and 1,000 nM], temsirolimus [(D Tem, 10 and 100 nM), Res [(E) 25 and 50 µM] and BEZ [(F) 10 and 100 nM)]. MDAH-2774 cells 
were seeded in 6-well plates at a density of 100,000 cells per well and allowed to proliferate for 24 h before treatment. Cells were treated with mTOR pathway 
inhibitors for 24, 48 and 72 h. At each time-point, cells were detached and mixed with an equal volume of trypan blue. A count of viable and dead cells was 
made using a Countess automated cell counter (Invitrogen). Error bars depict standard deviation, *p=0.01-0.05, **p=0.001-0.009, ***p<0.009.
Figure 4. Proliferation and survival analysis of SKOV3 cells following treatment with Rap [(A) 20 and 100 nM], everolimus [(B) Eve, 20 and 100 nM], deforo-
limus [(C) Def, 100 and 1,000 nM], temsirolimus [(D) Tem, 10 and 100 nM], Res [(E) 25 and 50 µM] and BEZ [(F) 10 and 100 nM]. SKOV3 cells were seeded 
in 6-well plates at a density of 100,000 cells per well and allowed to proliferate for 24 h before treatment. Cells were treated with mTOR pathway inhibitors 
for 24, 48 and 72 h. At each time-point, cells were detached and mixed with an equal volume of trypan blue. A count of viable and dead cells was made using 
a Countess automated cell counter (Invitrogen). Error bars depict standard deviation, *p=0.01-0.05, **p=0.001-0.009, ***p<0.009.
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Figure 6. Analysis of caspase 9 cleavage following mTOR pathway inhibition in SKOV3 (A) and MDAH-2774 (B) cells following treatment with Rap (20 and 
100 nM), Eve (20 and 100 nM), Def (100 and 1,000 nM), Tem (10 and 100 nM), Res (25 and 50 µM) and BEZ (10 and 100 nM). SKOV3 and MDAH-2774 
cells were treated with mTOR pathway inhibitors for 24, 48 and 72 h. At each time-point, cells were lysed and western blots were performed using an antibody 
recognising cleaved large fragment and total caspase 9. Developed western blots were analysed densitometrically using ImageJ software (National Institutes 
of Health). Caspase 9 cleavage was increased after 24 h in SKOV3 cells but was not maintained at 48 or 72 h. No increase in caspase 9 cleavage was seen in 
MDAH-2774 cells. Error bars depict standard deviation. Representative image shows extractions after 72 h (C).
Figure 7. Analysis of phosphorylated p70S6K protein expression following mTOR pathway inhibition in MDAH-2774 (A) and SKOV3 (B) cells following 
treatment with Rap (20 and 100 nM), Eve (20 and 100 nM), Def (100 and 1,000 nM), Tem (10 and 100 nM), Res (25 and 50 µM) and BEZ (10 and 100 nM). 
SKOV3 and MDAH-2774 cells were seeded in 6-well plates at a density of 100,000 cells per well and allowed to proliferate for 24 h before treatment. Cells 
were treated with mTOR pathway inhibitors for 24, 48 and 72 h. At each time-point, cells were lysed and protein extracted in Laemmli buffer. Western blots 
were performed using an antibody recognising phosphorylated p70S6K (Thr389). GAPDH was used as a reference.
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kinase on an ovarian tissue array. Ovarian cancer (n=70) tissue 
samples were probed with a p70S6K antibody by immunohis-
tochemistry using DAB staining. Three areas of each tissue 
sample were selected at random and total cells and total posi-
tive cells were counted in each area. An average percentage of 
positive cells was calculated. There was a significant decrease 
Figure 8. Immunohistochemistry for phosphorylated p70S6 kinase was performed on paraffin-embedded ovarian tissue clinical samples from a range of 
ovarian tumours. Three areas of tissue were analysed for percentage of positively stained cells. A significant decrease in phosphorylated p70S6K was detected 
in germ cell tumours in comparison to epithelial tumours (A). (B and C) Representative images of serous papillary carcinoma (epithelial) and a germ cell 
tumour, respectively. Error bars depict standard error.
Figure 9. Immunohistochemistry for phosphorylated p70S6 kinase was performed on paraffin-embedded ovarian tissue clinical samples from a range of 
ovarian tumours. Three areas of tissue were analysed for percentage of positively stained cells. No significant change was seen between individual stage of 
disease; however a significant difference was detected between early and late stage disease [(p=0.0461 (A)]. (B and C) Representative images of stage I and 
stage IV serous papillary carcinoma, respectively. Error bars depict standard error.
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in phospho-p70S6K protein expression in germ cell tumours 
in comparison to epithelial cell tumours (Fig. 8, p=0.0398). 
No significant change was seen in the grade of ovarian cancer 
(data not shown); however, phospho-p70S6 kinase shows a 
significant increase in later stages (Fig. 9).
Expression of mTOR components in ovarian cancer patients. 
It is becoming more widely accepted that an explorative test 
should be carried out for each set of samples to determine a 
suitable reference gene in each case (11,13). For this reason, we 
performed an analysis of reference gene stability in ovarian 
clinical tissue samples using the geNorm™ 12 gene kit. Eight 
clinical samples were selected to represent the whole cohort. 
The two most stable genes were RPL13A (ribosomal protein 
L13A; a gene that encodes a component of the 60S ribosomal 
subunit) and YWHAZ (a gene that encodes a 14-3-3 signal 
transduction protein). These reference genes were used in 
qPCR experiments involving clinical samples as they have 
been proven stable enough to provide robust normalisation.
Therefore, qPCR for mTOR, DEPTOR, rictor and raptor 
was carried out using the reference genes RPL13A and 
YWHAZ on cDNA synthesised from the extracted RNA 
from ovarian tissue of ovarian cancer patients (n=13) and 
non-affected controls (n=34). Data were analysed using the 
ΔCq method and an RQ value calculated by 2-ΔCq. Results show 
a significant increase in DEPTOR expression (p=0.0007) 
and a significant decrease in rictor expression (p=0.0388) in 
comparison to control (Fig. 10).
Discussion
In this study, using two different ovarian cancer cell lines and 
clinical samples, we investigated the effect of rapalogues as 
well as dual kinase inhibitors in ovarian cancer. We have used 
SKOV3 and MDAH-2774 cell lines as models for epithelial 
ovarian cancer. The cell lines differed in their cells of origin, 
SKOV3 cells are clear cell derived, and MDAH-2774 are 
endometrioid. Using these cell lines we were able to study the 
two forms of malignancy most associated with endometriosis 
(14-16). In future, a useful addition to this study should be the 
inclusion of primary malignant and non-malignant ovarian 
surface epithelial cells. All key components of mTORC1 
and mTORC2 complexes, i.e., mTOR, DEPTOR, rictor and 
raptor are expressed in both cell lines in a similar manner. 
The predominant component was raptor, with DEPTOR 
demonstrating minimal expression under basal (no treatment) 
conditions. Using high-resolution flow cytometry we demon-
strate for the first time a cytoplasmic and nuclear expression 
of mTOR and DEPTOR in MDAH-2774. Similar localisation 
was evident in SKOV3 corroborating previous data from our 
laboratory (10). Rictor and raptor appeared to be expressed 
primarily in the cytoplasm (data not shown). It is evident 
therefore, that under basal conditions both mTOR complexes 
are expressed at mRNA and protein level.
Furthermore, we assessed the expression of these genes 
in ovarian cancer patients (n=13) and controls (n=34). We 
demonstrate a significant increase in DEPTOR expression and 
a significant decrease in rictor expression in comparison to 
controls. In order to assess mTOR pathway component gene 
expression in a large cohort of patients (>50), we utilised the 
in silico analysis method Oncomine™. mTOR, DEPTOR and 
raptor expression was analysed, but due to the small sample 
size, rictor data was not available. mTOR gene expression 
was significantly higher (1.166-fold) in data from the Bonome 
dataset in ovarian carcinoma (n=185) patients compared to 
controls (n=10). DEPTOR gene expression was significantly 
Figure 10. Gene expression analysis of mTOR pathway components, mTOR, DEPTOR, rictor and raptor in ovarian clinical samples. cDNA was synthesised 
from mRNA extracted from ovarian tissue obtained from ovarian cancer patients and unaffected controls. qPCR was performed using primers for mTOR, 
DEPTOR, rictor and raptor corrected with YWHAZ and RPL13A (reference genes). Error bars depict standard error.
ROGERS-BROADWAY et al:  mTOR SIGNALLING AS A TARGETED APPROACH AGAINST OVARIAN CANCER142
higher (1.683-fold) in patients with ovarian serous adenocarci-
noma (n=43) compared to controls (n=10; Yoshihara dataset). 
There were no significant changes in the expression of raptor 
between ovarian serous adenocarcinoma patients (n=43) and 
controls (n=10; Yoshihara dataset).
As mentioned, this study investigated the effects of mTOR 
pathway inhibition in vitro. Western blot experiments indicated 
cleavage of caspase 9 after 24-h treatment which was then 
decreased by 48 h in SKOV3 cells. This indicates that initial 
response to mTOR inhibitor treatment is to induce apoptosis 
but this effect is rescued by 48 h of treatment. Caspase 9 is an 
initiator caspase which cleaves the pro-form of caspase 3 to 
induce apoptosis. However, there was no cleavage of caspase 3 
in either of the cell lines following treatment with mTOR 
inhibitors (data not shown), suggesting that there is limited 
impact on apoptotic events. This data was further supported 
by proliferation assays showing no change in dead cell number 
over 72 h. Results showing no significant change in dead cell 
number over the course of the experiment in any case indicate 
that the effects of mTOR pathway inhibition are cytostatic 
as opposed to cytotoxic. This data is supported by previous 
research which shows that rapamycin and temsirolimus cause 
cell cycle arrest at G0/G1 phase (17), whereas Eve treatment 
reduced viable cell number, but was not able to induce apop-
tosis in SKOV3 cells (18).
The inhibitory effects of Res and BEZ on SKOV3 cells 
were significantly greater for these dual mTOR/PI3 kinase 
inhibitors than for the rapalogues alone. This suggests that 
additional targeting of PI3 kinase increases inhibitory effi-
cacy in these ovarian cancer cells. In the more proliferative 
MDAH-2774 cell line, 100 nM BEZ treatment profoundly 
decreased the number of viable cells to almost basal level; 
however dual mTOR and PI3 kinase inhibitors were not 
more effective than inhibition by rapamycin or rapalogue in 
these cells. The lower efficacy of dual inhibitors observed in 
MDAH-2774 cells may be due to the negative feedback loop 
directed to PI3 kinase that is relieved on mTOR inhibition and 
can induce PI3 kinase signalling via Akt to cause upregula-
tion in mTORC2 signalling (19). Dual mTOR and PI3 kinase, 
or mTORC1 and mTORC2 inhibitors are able to target both 
mTORC1 signalling and the after-effect of mTORC2 signalling 
and therefore provide better repression of the mTOR pathway 
(20,21). There is also evidence that a negative feedback loop 
exists from mTOR to the MAP kinase pathway (22) and inhi-
bition of both the MAP kinase and PI3 kinase pathways has 
proven to be more effective than targeting solely PI3 kinase 
(20). Collectively, these data demonstrate that these inhibitors 
act in a cell-specific manner within the microenvironment of 
ovarian cancer.
Phosphorylation status of p70S6K was also assessed to 
obtain a better understanding of the effects of these inhibitors 
on mTORC1 activity. Rapamycin, rapalogues and BEZ (at high 
concentration in MDAH-2774) completely dephosphorylated 
p70S6K in both cell lines. In SKOV3 cells, treatment with 
50 µM of Res also dephosphorylated p70S6K. However, Res 
did not dephosphorylate p70S6K in MDAH-2774 cells. These 
data corroborate previous findings on p70S6K using BEZ 
in neuroblastoma cells (23), temsirolimus and everolimus 
in EGFR mutant lung cancer cells, PC-9, and HCC827 (24). 
In one of our in vitro models, Res had little effect on the 
phosphorylation status of p70S6K. This again could be a cell-
specific effect since Res inhibits p70S6K in other cell lines 
such as the osteoblast-like MC3T3-E1 cells (24), or the human 
nasopharyngeal carcinoma (NPC) cells (26) to name a few.
Given the importance of p70S6K in ovarian cancer, we 
mapped the protein expression of this phospho-p70S6K in 70 
ovarian cancer patients and controls. We demonstrate for the 
first time a significant increase in staining for phospho-p70S6K 
with worsening stage. Since p70S6K can be a prerequisite 
of tumour metastasis (27), targeting this kinase particularly 
in patients with high stage tumours could be of therapeutic 
value. Recently it has been shown that phosphorylated p70S6K 
predicted tamoxifen resistance in postmenopausal breast 
cancer patients (28). Future studies should concentrate on 
immunostaining for phosphorylated p70S6K in a larger cohort 
of patients in order to define whether this kinase is of a diag-
nostic or prognostic value in ovarian cancer.
This study highlights the need for ‘tailor-made’ therapies 
against ovarian cancer depending on the gene expression 
profile of the patient. The non-apoptotic effects of the mTOR 
pathway inhibitors used in this study may exclude them from 
being effective single agent therapies in the treatment of malig-
nancy. However, it has been shown that rapalogue treatment 
is able to potentiate the apoptotic effects of tamoxifen, doxo-
rubicin, UCN-01 and cisplatin treatment in vitro, indicating 
that mTOR pathway inhibitors may be useful in combinatorial 
therapeutic approaches to cancer treatment (18,29-31). Using 
mTOR pathway inhibitors may therefore allow for lower doses 
of cytotoxic chemotherapeutic agents in cancer treatment and 
therefore a reduction in the harmful side-effects brought about 
by these drugs (31).
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